Pembrolizumab-induced nephrotoxicity in a patient with breast cancer

By sjmartinez • April 29, 2024

Alkassis S, Fitzsimmons K, Hurvitz S. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241248362. doi: 10.1177/17588359241248362. PMID: 38680292; PMCID: PMC11047248.

Tags: adverse event management, breast cancer, Checkpoint Inhibitor, Fellow, Hematology/Oncology, immune-related adverse events, immune-related adverse events < immunotherapy, immunotherapy, Publications

Characteristics of clinical trials associated with appeal and return on investment to participants, A Review and Framework

Fernandez Turizo MJ, Velez MA, Glenn B, Cummings AL, Segarra-Vazquez B, Gorbatov S, Park SJ, Shen C, Lind-Lebuffe JP, Unger JM, Garon EB. Characteristics of[...]

IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation

Sharma G, Gutierrez M, Jones AE, Kapoor S, Jaiswal AK, Neeb ZT, Rios A, Dorairaj P, Thaxton ML, Lin TL, Tran TM, Kabbani LES, Ritter[...]

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]